You are here

  • Home
  • Archive
  • Volume 79, Issue 2
  • Efficacy and safety of ixekizumab through 52 weeks in two phase 3, randomised, controlled clinical trials in patients with active radiographic axial spondyloarthritis (COAST-V and COAST-W)

Citation Tools

Article menu
XML
Spondyloarthritis
Efficacy and safety of ixekizumab through 52 weeks in two phase 3, randomised, controlled clinical trials in patients with active radiographic axial spondyloarthritis (COAST-V and COAST-W)

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Dougados M, Wei JC, Landewé R On behalf of COAST-V and COAST-W Study Groups, et al
Efficacy and safety of ixekizumab through 52 weeks in two phase 3, randomised, controlled clinical trials in patients with active radiographic axial spondyloarthritis (COAST-V and COAST-W)
Annals of the Rheumatic Diseases 2020;79:176-185.